Neurocrine Biosciences, Inc. Share Price Deutsche Boerse AG
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130 EUR | -1.03% | -0.08% | +9.42% |
Sales 2024 * | 2.22B 2.04B 185B | Sales 2025 * | 2.54B 2.34B 212B | Capitalization | 14.32B 13.18B 1,192B |
---|---|---|---|---|---|
Net income 2024 * | 430M 396M 35.8B | Net income 2025 * | 661M 608M 55.04B | EV / Sales 2024 * | 5.55 x |
Net cash position 2024 * | 2B 1.84B 166B | Net cash position 2025 * | 2.79B 2.57B 233B | EV / Sales 2025 * | 4.53 x |
P/E ratio 2024 * |
34.7
x | P/E ratio 2025 * |
22.6
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -1.03% | ||
1 week | -0.08% | ||
Current month | -3.06% | ||
1 month | +4.33% | ||
3 months | +5.43% | ||
6 months | +30.55% | ||
Current year | +9.42% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 01/92/01 |
Director of Finance/CFO | 44 | 01/17/01 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 30/21/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01/99/01 |
George Morrow
BRD | Director/Board Member | 72 | 01/15/01 |
Kevin Gorman
FOU | Founder | 66 | 01/92/01 |
Date | Price | Change | Volume |
---|---|---|---|
17/24/17 | 130 | -1.03% | 0 |
16/24/16 | 131.4 | +2.26% | 15 |
15/24/15 | 128.5 | +2.59% | 9 |
14/24/14 | 125.2 | -2.15% | 20 |
13/24/13 | 128 | -1.65% | 15 |
Delayed Quote Deutsche Boerse AG, May 17, 2024 at 11:31 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+36.24% | 12.55B | |
-24.95% | 8.45B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock